Galderma has announced that the Chinese National Medical Products Administration (NMPA) has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.
This approval follows successful authorisations and launches of Relfydess in more than 35 markets worldwide. Galderma expects to commercially launch Relfydess in China in H2 2027.
Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals. It is optimised for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.
At a time when patients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Relfydess’ introduction to China will help to meet the increasing needs of this large and diverse market by providing an innovative new treatment option. Relfydess is developed and manufactured at Galderma's Aesthetic Center of Excellence in Uppsala, Sweden.
With Relfydess’ approval in China, Galderma expands its footprint and further strengthens its Injectable Aesthetics leadership within the fast-growing Asia-Pacific market.
